Showing results (191-200 of 3,351) with videos related to
Sort By:
Pageof 336
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.The Lancet. Oncology|July 4, 2019
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indicationsMohammad Alyami, Martin Hübner, Fabian Grass, et al.The Lancet. Oncology|June 2, 2019
Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impactDanielle Rodin, Emily A Burger, Rifat Atun, et al.The Lancet. Oncology|July 2, 2019
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Carla M L van Herpen, Cristina Saura, et al.The Lancet. Oncology|January 27, 2022
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trialMin Yan, Quchang Ouyang, Tao Sun, et al.The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.The Lancet. Oncology|April 9, 2022
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based studySean McPhail, Ruth Swann, Shane A Johnson, et al.The Lancet. Oncology|March 31, 2022
Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization GroupJordan Gilleland Marchak, Salome Christen, Renée L Mulder, et al.The Lancet. Oncology|October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.The Lancet. Oncology|September 17, 2018
The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016Pageof 336